(Q35528462)

8 August 2017

title

CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap (English)

1 reference

National Institutes of Health

8 August 2017

0 references

0 references

0 references

Centers for Disease Control and Prevention

21

object named as

National Institutes of Health

0 references

22

object named as

Centers for Disease Control and Prevention

1 reference

8 August 2017

John T Belisle

8

0 references

Anne F. Luetkemeyer

10

object named as

Annie Luetkemeyer

1 reference

8 August 2017

16

Susan Swindells

1 reference

8 August 2017

15

Mamodikoe Makhene

1 reference

8 August 2017

Payam Nahid

1

1 reference

8 August 2017

Jussi Saukkonen

2

1 reference

8 August 2017

William R Mac Kenzie

3

1 reference

8 August 2017

John L Johnson

4

1 reference

8 August 2017

Patrick P J Phillips

5

1 reference

8 August 2017

Janet Andersen

6

1 reference

8 August 2017

Erin Bliven-Sizemore

7

1 reference

8 August 2017

W Henry Boom

9

1 reference

8 August 2017

Thomas B Campbell

11

1 reference

8 August 2017

Kathleen D Eisenach

12

1 reference

8 August 2017

Richard Hafner

13

1 reference

8 August 2017

Jeffrey L Lennox

14

1 reference

8 August 2017

M Elsa Villarino

17

1 reference

8 August 2017

Marc Weiner

18

1 reference

8 August 2017

Constance Benson

19

1 reference

8 August 2017

William Burman

20

1 reference

8 August 2017

language of work or name

English

0 references

publication date

1 October 2011

1 reference

8 August 2017

number of pages

8

1 reference

American Journal of Respiratory and Critical Care Medicine

inferred from page(s)

published in

1 reference

8 August 2017

volume

184

1 reference

8 August 2017

issue

8

1 reference

8 August 2017

page(s)

972-979

1 reference

Geographic differences in time to culture conversion in liquid media: Tuberculosis Trials Consortium study 28. Culture conversion is delayed in Africa

8 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208659

Immunological biomarkers of tuberculosis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208659

Global tuberculosis drug development pipeline: the need and the reality.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208659

Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208659

Early clinical development of anti-tuberculosis drugs: science, statistics and sterilizing activity

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208659

Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208659

Biomarkers of disease activity, cure, and relapse in tuberculosis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208659

Rapid diagnosis of tuberculosis through the detection of mycobacterial DNA in urine by nucleic acid amplification methods

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208659

Biomarkers for tuberculosis disease activity, cure, and relapse

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208659

Using animal models to develop new treatments for tuberculosis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208659

Banking of biological fluids for studies of disease-associated protein biomarkers

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208659

Biomarkers for TB treatment response: challenges and future strategies

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208659

Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208659

Biomarkers of treatment response in clinical trials of novel antituberculosis agents

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208659

Recurrent tuberculosis in the United States and Canada: relapse or reinfection?

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208659

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208659

Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208659

Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208659

Surrogate end points in clinical trials: are we being misled?

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208659

Surrogate endpoints in clinical trials: definition and operational criteria

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208659

Tuberculosis drug development pipeline: progress and hope

27 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1164%2FRCCM.201105-0827WS

Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1164%2FRCCM.201105-0827WS

Timing of relapse in short-course chemotherapy trials for tuberculosis.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208659

Statistical validation of intermediate endpoints for chronic diseases

26 September 2018

1 reference

12 December 2020

Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months

1 reference

12 December 2020

Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research

1 reference

12 December 2020

Are surrogate markers adequate to assess cardiovascular disease drugs?

1 reference

12 December 2020

Biomarkers and surrogate end points in clinical trials of tuberculosis treatment

1 reference

12 December 2020

Surrogate and mediating endpoints: current status and future directions

1 reference

12 December 2020

10.1164/RCCM.201105-0827WS

Identifiers

DOI

1 reference

8 August 2017

1 reference

8 August 2017

1 reference